Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

N.Y. AG sets sights on Forest trials

Executive Summary

New York Attorney General Eliot Spitzer issues a request to Forest for information related to off-label clinical trials and promotion of its products, company says June 29. The AG is "concerned that Forest may be in violation of New York state law"; Forest maintains it has been in compliance with all applicable laws. Spitzer recently brought suit against GlaxoSmithKline, alleging the company concealed results from pediatric studies of its antidepressant Paxil (1"The Pink Sheet" June 7, 2004, p. 3). Forest issued a press release reiterating the results of Celexa and Lexapro pediatric studies after the Paxil suit was filed (2"The Pink Sheet" June 28, 2004, p. 30)...
Advertisement

Related Content

GSK Faces New York Suit Over Paxil: Publish Or Punish?
GSK Faces New York Suit Over Paxil: Publish Or Punish?

Topics

Advertisement
UsernamePublicRestriction

Register

PS044294

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel